Latest total assets for XLO: $160M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Xilio Therapeutics (XLO) currently reports a total assets of $160M as of March 2026. That compares with $100M in the prior-year period — up 57.6% year over year. Use the charts on this page to explore Xilio Therapeutics's total assets history and peer comparisons.
Xilio Therapeutics's total assets increased from $100M to $160M — a 57.6% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Xilio Therapeutics reported $160M in total assets as of March 2026. That compares with $100M in the prior-year period — up 57.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total assets of $160M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Xilio Therapeutics, and consider following XLO for alerts when major investors trade the stock.
Xilio Therapeutics is classified in the Healthcare sector. On total assets, it currently shows $160M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing XLO with unrelated industries.